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A variety of observational studies have found that dietary factors
predict the incidence of cancer and precancerous lesions. Different
sub-sets of these studies have been summarized to propose that
beta-carotene or vitamin A is the active component (Ziegler, 1991;
Hunter and Willett, 1994), that vitamin C is the active component
(Block, 1991) or that the association is more consistent for fruit
and vegetables as a group than for any particular nutrient
(Steinmetz and Potter, 1991; Block et al, 1992). Some studies have
used cervical intra-epithelial neoplasia (CIN) and invasive cervical
cancer as the outcomes, but results disagree as to whether the
strongest associations are for foods rich in beta-carotene and/or
vitamin C and/or folate (Potischman, 1993). This inconsistency
could be due to the differing accuracy of the dietary instruments
for measuring the various vitamins, inadequate control for impor-
tant confounders or because the nutrients are acting as markers for
some other constituent in food. However, these studies do raise the
possibility that increasing the intake of micronutrients might
increase the regression rates or reduce the progression rates of
minor cervical abnormalities – minor atypia and CIN I – to more
severe abnormalities and cervical cancer. Although these nutrients
are frequently described as antioxidants, some or all of them
also exhibit other properties including cellular growth control,
immunomodulation and gap junction modulation, which may be
important after the initiation phase of carcinogenesis (Gerster,
1995). A variety of animal and in vitro studies have found that
high doses of beta-carotene or vitamin C, given singly, have bene-
ficial effects in retarding the promotion and progression of cancer
(Gerster, 1995).
In 1991, we commenced a trial using 30 mg beta-carotene or
500 mg vitamin C daily in women with minor atypia or stage I
CIN (CIN I) to investigate this possibility in humans. In this paper,
we report the effect on the progression and regression rates during
2 years of follow-up.
MATERIALS AND METHODS
We conducted a factorial, randomized, double-blind trial allocat-
ing equal numbers of women to an oral daily dose of either 30 mg
beta-carotene or 500 mg vitamin C or both or neither. Subjects
were stratified according to initial severity of the lesion (CIN I or
minor squamous atypia) and randomized in permuted blocks of
size 8 within strata. A diagnosis of the presence of human papil-
loma virus (HPV) alone was not considered sufficiently severe
for inclusion in this trial. Minor atypia is a minimal change, not
sufficient to be categorized as CIN I; it excludes inflammatory
changes. Probable and definite CIN II are both referred to as
CIN II hereafter.
The study was conducted at the Colposcopy Clinic in Sydney,
Australia, run by Family Planning New South Wales (FPNSW)
where clients with abnormal pap smears from six of the FPNSW
clinics in Sydney are examined. All cytology slides are assessed
by one cytology laboratory. The population using FPNSW services
are better educated, more likely to be single and have higher status
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jobs than the general population (Young and Williamson, 1986).
At the Clinic, a colposcopic examination and biopsy is performed
by trained female medical staff who are judged competent by
national audit criteria. All biopsies are assessed by one laboratory.
At the start of the trial in 1991, the usual clinic policy was to
advise women with CIN I that the 2-year progression rate was
about 30% and that they could choose immediate ablation or
6-monthly follow-up by pap smear and colposcopy, with biopsy
when clinically indicated. The majority of women in this clinic
were choosing follow-up. Women with minor atypia were not
offered the option of ablation and all were followed up at
6-monthly intervals by pap smear and colposcopy. Ethical
approval for the trial was given by the University of Sydney
Human Ethics Committee and the Ethics Committee of FPNSW
on the understanding that women would make this choice before
being informed of the existence of the trial. Sample size calcula-
tions were based on the accepted view at that time that a third of
lesions would progress, a third would regress and a third would
have no change over the 2-year duration (Campion et al, 1986).
We estimate that 70 people would be needed in each of two arms
comparing beta-carotene vs placebo or vitamin C vs placebo, in
order to have 80% power to detect an increase in regression rate
from 30% to 55%, and a reduction in progression rate from 30% to
10%, over 2 years as statistically significant at the 2-sided 5%
level (Fleiss, 1981). As it was assumed the effects would be
independent, a factorial design was used which gave a final sample
size of 35 in each of four groups. The effect size of 2- to 3-fold was
based on the results of the earlier observational studies (Block,
1991; Ziegler, 1991; Hunter and Willett, 1994).
Eligible women were those electing follow-up, aged 18 years or
older, in whom no diagnosis of or treatment for a cervical abnor-
mality had occurred in the previous 12 months. The diagnosis had
to be based on having at least three of five assessments (one
colposcopy and two independent assessments of each of the
screening pap smear and the biopsy slides) grading the lesion as at
least CIN I or minor atypia. Women were ineligible if any assess-
ment was CIN III, if two assessments were CIN II or more severe,
or if either reading of the histology slide returned a diagnosis of
greater than CIN I; any women with abnormalities falling in these
categories were contacted and offered treatment. These eligibility
criteria were drawn up in recognition of the difficulties of
assessing low-grade abnormalities of the cervix (Morrison et al,
1988) to ensure that there was a confirmed lesion at the start of the
trial and to exclude those who might have CIN II. Additional eligi-
bility criteria only ascertainable on interview were: anticipated
residence in Australia for most of the next 2 years; no other health
problems; not allergic to soya beans; no immediate plans for preg-
nancy; not taking more than 6 mg/day beta-carotene, 5000 IU/day
vitamin A or 75 mg/day vitamin C routinely (high doses during a
cold were acceptable). Routine use of other vitamins, minerals or
herbal preparations was acceptable. If informed consent was
obtained, a 1-month supply of capsules was left, with the explana-
tion that it was a run-in period (but women were not told that
these were placebo capsules). One month later, compliance and
continued interest was assessed by phone call. If compliance was
greater than 80%, the woman was randomized and sent a 6-month
supply of study capsules; if less, a further run-in period was done
if the woman was still interested.
A questionnaire was administered at the commencement of the
run-in period ascertaining smoking levels and fruit and vegetable
intake, using the summary questions from the Health Habits and
History Questionnaire (Block, 1989), self-reported height, weight
and smoking habit. Subjects were phoned every month to
encourage and assess compliance and to ask about the incidence of
various potential side-effects. Menstruation was ascertained as it
had been decided that pregnant women, or women planning
pregnancy, should be told to stop taking the capsules.
Subjects were seen in person by the research assistant at their
6-monthly visits to the Colposcopy Clinic. Compliance was
assessed by pill-count at this visit. Clinic doctors knew the study
was being conducted, but did not know which clients were in this
study, as participants were not given any priority in the appoint-
ment system. After guidelines for treatment of patients were
altered in 1994 (National Health and Medical Research Council,
1994), study participants’ records had to be marked to allow
continued management according to the former, stricter system for
the duration of their participation in the trial. However, colpo-
scopists remained blind to which group women were in. Subjects
were free to withdraw from the study at any time. In accordance
with Clinic policy, they could also elect to have ablation during the
follow-up, despite no evidence of progression. Participants who
decided to stop taking study capsules, but did not have ablation,
were asked for permission to continue monitoring medical records
for endpoints. As the 2-year point for the trial generally fell
between examinations, participants were asked to continue taking
capsules until the next examination.
At the end of the trial, all essential data were re-entered by a
single individual who was blind to group allocation; medical
records were examined and any unclear endpoints referred for
review to a medical practioner, who was also blind to group
assignment. Progression was deemed to have occurred when a
result of CIN II or worse was obtained on any of pap smear,
colposcopy or biopsy. Regression was defined as a normal result,
with or without HPV, on both colposcopy and pap smear, on two
successive clinic visits. Time to an endpoint was measured from
the date of randomization to the date of the last clinic visit. The
other categories of follow-up were: censoring at the final visit due
to no change in the lesion, loss to follow-up, discharge following
only one normal reading, ablation without evidence of progres-
sion, and withdrawal from the trial. Participants who ceased taking
study capsules and agreed to permit us to monitor their records
were followed until their 2-year visit; if permission was not given,
the last visit to the colposcopy clinic prior to withdrawal was used
as the withdrawal date.
Randomization was managed by the National Health and
Medical Research Council Clinical Trials Centre, independently of
the investigators. All capsules were identical in appearance and
blister-packed in trays of 14 and marked with the names of the
days to aid compliance. The randomization code for groups was
not broken until after all statistical analyses had been completed.
Synthetic vitamins in a soya bean oil base were manufactured
with a 10% higher potency to allow for loss over time. Samples
from the two storage locations were retested by the manufacturer
(RP Scherer, Melbourne, Victoria) half-way through the trial in
December, 1993 and contained, on average, 516.8 mg vitamin
C and/or 30.8 mg beta-carotene.
An intention-to-treat analysis was done, using Cox’s propor-
tional hazards regression in BMDP (BMDP Statistical Software
Inc, Los Angeles, CA) to test for interaction effects between the
vitamins using maximum likelihood chi-square (c2) statistics, and
to estimate the hazard ratios and their 95% confidence intervals.
The proportional hazards assumption was checked using log–log1450 D Mackerras et al
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plots and by testing for an interaction between each variable and
the logarithm of time to an endpoint. The assumptions held
overall, although there was a suggestion that the assumption did
not hold for progressions because the pattern of progressions in the
groups differed in the first and second years of follow-up, but the
small number of progressions made it difficult to assess.
Progression and regression are competing risks, that is, women
who experience one of these endpoints will not experience the
other endpoint for a particular abnormality. Kaplan–Meier curves
are the standard method for analysing time to an endpoint.
However, this method incorrectly treats a woman who experiences
a progression, for example, as censored when estimating the
probability of a regression, and hence overestimates probability
(Gaynor et al, 1993). Therefore, the probability curves for
regression and progression were separately calculated from the
cumulative incidence curves instead (Pepe and Mori, 1993).
RESULTS
Of the 420 women invited to participate, 153 entered the run-in
phase and 147 were randomized. Six did not return for follow-up,
leaving 141 with analysable results. The first woman was random-
ized in August 1991 and the last in December 1993. The final
follow-up visit occurred in November 1995.
Baseline characteristics, except the proportion of current
smokers, were evenly distributed among the groups (see Table 1).
There were 49 and 92 randomized in the CIN I and minor atypia
strata respectively. There were 13 progressions to CIN II and 43
regressions to normal (Table 2), of which 10 and 29 respectively
occurred before 2 years of follow-up. Among the remaining 102
participants, the median follow-up was 23 months: 50 completed 2
years or longer of follow-up, seven came up to 4 months early for
their ‘2-year’ visit, 21 withdrew or were lost to follow-up, 13 were
prematurely discharged from the Colposcopy Clinic, and 11 chose
ablation despite no evidence of progression. All categories of
censoring and drop-out were evenly distributed among the four
groups. Of the 18 women who decided to stop taking study
capsules, eight were in the double control group and the other 10
were evenly distributed among the other three groups. Overall,
average compliance was 91%, not counting the period after
women chose to discontinue study capsules, but including the
interval while they were advised not to take them owing to planned
or actual pregnancy.
Table 1 Baseline characteristics of 141 randomized women by treatment groups (Sydney, 1991–93), showing mean (SD) or percentages
Control Beta-carotene Vitamin C Both
(n = 35) (n = 36) (n = 35) (n = 35)
Age (yrs) 28 (8) 31 (9) 31 (10) 29 (9)
Height (cm) 164 (7) 166 (6) 165 (7) 166 (7)
Weight (kg) 60 (9) 62 (9) 61 (9) 61 (12)
BMI (kg m–2) 22.2 (3.3) 22.5 (3.2) 22.5 (4.0) 22.2 (3.6)
Fruit servings per week* 11 (7) 9 (6) 13 (7) 10 (5)
Vegetable servings per week** 13 (8) 12 (8) 16 (8) 15 (8)
Current smokers 17% 25% 34% 37%
Taking other vitamins & minerals 37% 31% 31% 37%
*Servings of fruit excluding juice; **servings of vegetables excluding potatoes and salad.
Table 2 Number of person-years of follow-up, regressions and progressions, and hazard ratios for regression and progression with and without interaction, by
randomized group (Sydney, 1993–5)
Person-years Number of Regression hazard Number of Progression hazard
at risk regression events ratio (95% CI) progession events ratio (95% CI)
Vitamin C No Yes Total No Yes Total No Yes Total No Yes Total No Yes Total
Beta-carotene No 59 61 121 10 9 19 1 0.77 1 3 2 5 1.00 0.64 1.00
referent (0.21, 2.58) referent referent (0.11, 3.84) referent
Yes 56 51 108 16 8 24 1.79 1.02 1.58 1 7 8 0.32 2.57 1.75
(0.80, 4.01) (0.40, 2.60) (0.86, 2.93) (0.03, 3.12) (0.66, 9.98) (0.57, 5.36)
Total 116 113 229 26 17 43 1 0.65 4 9 13 1.00 2.40
referent (0.35, 1.21) referent (0.74, 7.80)
The person-years at risk table shows the total length of exposure to each treatment combination in person-years for the 2-year study. For the hazard ratio
tables, the figures labelled ‘Total’ show the ratio of the hazard (e.g. of progression) in the treated group relative to the corresponding placebo group if no
interaction is assumed (e.g. 1.75 for beta-carotene; 2.40 for vitamin C) while the internal cells show the hazard ratios relative to the double placebo group if an
interaction is assumed (e.g. 2.57 for both treatments combined but 0.32 and 0.64 respectively for beta-carotene and vitamin C alone).Vitamins and minor cervical abnormalities 1451
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The number of regressions and progressions by intervention
group is shown in Table 2. The most notable observation is that
seven of the progressions were in the groups receiving both
vitamin C and beta-carotene, compared to a total of six progres-
sions in the other three groups. This occurred even though the
person-years at risk was slightly less in the group receiving both
vitamins than in the other groups. To quantify the magnitude and
statistical significance of this observation and other possible asso-
ciations, hazard ratios (HR) and their 95% confidence intervals
(CI) for both outcomes, with and without an interaction effect, are
also shown in Table 2. Those randomized to beta-carotene had
slightly higher, non-significant, regression rates (HR = 1.58, 95%
CI: 0.86–2.93, P = 0.14) than those not randomized to beta-
carotene and those randomized to vitamin C had slightly lower,
non-significant, regression rates (HR = 0.65, 95% CI: 0.35–1.21,
P = 0.17) than those not randomized to vitamin C (Table 2 and
Figure 1). There was no evidence of an interaction between the
compounds on the regression rate (P = 0.64). In a model with no
interaction, there was a non-significant slightly higher progression
rate in those randomized to beta-carotene (HR = 1.75, 95% CI:
0.57–5.36, P = 0.32) or vitamin C (HR = 2.40, 95% CI: 0.74–7.80,
P = 0.13). There was a statistically significant interaction effect
(P = 0.052), indicating that those receiving a combined dose of
both beta-carotene and vitamin C were more likely to progress
than those receiving neither (HR = 2.57, 95% CI: 0.66–9.98;
Table 2 and Figure 2). Although not statistically significant, the
95% confidence intervals rule out large beneficial effects of
either compound on the progression rate. None of these results
was altered by adjusting for differences in baseline smoking
prevalence.
DISCUSSION
Since the commencement of our trial, several randomized
controlled trials have reported on the effect of beta-carotene on
various grades of cervical lesions. Using a 10 mg day-1 dose in a
randomized trial with a 3-month follow up, de Vet et al (1991) found
a small, non-significant difference in regression that changed direc-
tion depending on whether the broad or strict definitions of regres-
sion were used (see Table 3). Using a longer follow-up in women
with less severe lesions, neither Fairley et al (1996) nor Romney
et al (1997) found a difference in regression rates over 9–12 months
with a daily dose of 30 mg. Fairley et al (1996) found no difference
in the quantity of DNA from human papilloma virus between the
groups and Romney et al (1997) found a non-significant adverse
effect of beta-carotene on persistence of HPV. Based on the four
randomized trials, the results of Manetta et al (1996), who found a
70% regression of CIN I and II over 6 months in an uncontrolled
trial of beta-carotene, must be regarded as being due to spontaneous
regression rather than a positive effect of beta-carotene.
None of the studies, including ours, had many progression
endpoints even in the control groups. However, the slightly
favourable, non-significant, effect of beta-carotene on regression
rates in our study needs to be viewed together with the slightly
unfavourable, non-significant, effect on progression rates.
There are several important differences among the four studies.
Firstly, we excluded anyone who had a histological diagnosis of
CIN II or III whereas about two-thirds of the Dutch subjects (de
Vet et al, 1991) and half the American subject (Romney et al,
1997) had these more severe lesions. Our study subjects generally
had more severe lesions than those of Fairley et al (1996) and we
did not allow the presence of HPV alone as a sufficient entry crite-
rion. In addition, our entry criteria were based on three forms of
assessment. We also had a considerably longer follow-up and a
more stringent criterion for assessing regression than the other
studies. We required a normal cervix to be documented on two
successive pap smear and colposcopic examinations, whereas the
other trials required only one examination, and some included
regression to a less severe lesion as a regression endpoint.
Whatever the differences in design, the studies collectively
suggest that there is unlikely to be a protective effect of beta-
carotene on the natural history of cervical precancers.
The pilot study for this trial showed an increase in beta-carotene
levels from 2.7 (SD 2.3) mmol l-1 to 4.1 (SD 2.3) mol l-1 over
2 months. As expected, retinol levels did not change substantially
(2.5 ± 0.6 mmol l-1 at baseline; 2.6 ± 0.5 mmol l-1 at 2 months).
Others have reported that beta-carotene levels in serum and cervical
cells increase to a maximum after 3 months when a 30 mg dose is
used (Manetta et al, 1996). Hence, lack of an effect should not be
attributed to lack of transport of beta-carotene into the cervix.
The non-significant effects of vitamin C in decreasing
regression rates and increasing progression rates are both in
Figure 1 Cause-specific curves showing the probability of a lesion
regressing in each treatment group. The numbers of women in the study at
entry and every 6 months thereafter were: 141, 132, 106, 88, 48, 9
Figure 2 Cause-specific curves showing the probability of a lesion
progressing in each treatment group. The numbers of women in the study at
entry and every 6 months thereafter were: 141, 132, 106, 88, 48, 91452 D Mackerras et al
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unfavourable directions in our study. This seems to be the first trial
to investigate the effect of vitamin C, either alone or in conjunction
with beta-carotene, on cervical dysplasia, although a small quan-
tity of 10 mg of vitamin C was used as the placebo in a trial inves-
tigating the effect of folic acid (Butterworth et al, 1982). One
suggestion from our study is of a possible interaction between
beta-carotene and vitamin C in increasing the progression rate.
Vitamin C is found in the aqueous phase whereas beta-carotene is
found on the inside cell membranes and tocopherols on the surface
of cell membranes. Using a soybean lipoxygenase model, Niki
et al (1995) have recently concluded that there should be no
interaction between vitamin C and beta-carotene as antioxidants.
However, our results support the possible existence of other mech-
anisms whereby an interaction might take place.
Beta-carotene has been tested in several other epithelial cancers.
Various studies have found reductions in oral leukoplakia using
beta-carotene, especially when combined with retinol, in subjects
using tobacco or alcohol (Garewal et al, 1993). However lung
cancer rates were slightly higher in Finnish smokers given beta-
carotene (Alpha-tocopherol Beta-carotene Prevention Study
Group, 1994) but overall cancer incidence and death rates were not
raised in groups containing fewer smokers (Greenberg et al, 1996;
Hennekens et al, 1996). In trials of people with a history of
asbestos exposure, a combined dose of beta-carotene and retinol
led to a slightly elevated incidence of lung cancer (Omenn et al,
1996) whereas another study found no differences in sputum
atypia over a shorter period (McLarty et al, 1995). There does not
seem to be another trial that has used beta-carotene combined
with vitamin C. Trials using adenomatous colonic polyps as the
outcome have tested various other combinations of beta-carotene,
vitamin C, vitamin E and retinol (McKeown-Eyssen et al, 1988;
DeCosse et al, 1989; Roncucci et al, 1993; Greenberg et al, 1994;
MacLennan et al, 1995). Only Roncucci et al (1993), who used
1000 mg vitamin C plus 70 mg alphatocopherol plus 9 mg retinol
(not beta-carotene), have found a favourable effect on the recur-
rence rate of adenomatous polyp.
The doses used in this and other studies were much higher than
could be obtained from the diet. For example, Brown et al (1989)
have shown that the rise in serum beta-carotene following a 12 mg
dose of beta-carotene as a supplement is substantially higher than
29 mg consumed in carrots. This raises the possibility that the low
intakes of beta-carotene and/or vitamin C described in epidemio-
logical studies are risk markers rather than causal factors. It is also
possible that intakes at the upper level of the dietary range
throughout life may be beneficial, whereas pharmacological doses
are inactive or deleterious. Our study does not address these ques-
tions. However, our results do contradict those of animal and in
vitro work suggesting that high doses of these compounds would
reduce the promotion of carcinogenesis.
The findings of our study and others provide a reminder of the
importance of conducting randomized trials in humans rather than
assuming that small, probably confounded, associations and
animal models are sufficient information on which to base thera-
peutic or preventive recommendations. In view of the lack of
effect, it is worth noting that the public is receiving different infor-
mation from other sources. A number of women eligible for our
trial had already decided to take antioxidant vitamins and did not
wish to be randomized with the possibility of receiving the
placebo. The currently available evidence suggests that high doses
of these compounds are unlikely to increase the regression or
decrease the progression of minor atypia and CIN I.
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